Pharma Focus Asia

Renibus Therapeutics Introduced First-of-its-Kind RBT-1 for Reducing Post-Operative Complications

Renibus Therapeutics has introduced first-of-its-kind RBT-1 to reduce the risk of post-operative complications in patients undergoing cardiothoracic surgery.

RBT-1, a combination of stannic protoporfin and iron sucrose, has shown promising potential in inducing various pathways related to anti-inflammation, antioxidant activity, and iron scavenging. 

The Phase 2 study of RBT-1, registered as NCT04564833, is a significant milestone in its development. This randomised, double-blind, multi-centre, placebo-controlled trial evaluated the efficacy of RBT-1 in patients undergoing elective coronary artery bypass graft (CABG) and/or cardiac valve surgery. 

The study yielded positive final results, meeting the primary biomarker endpoint as well as several key clinical outcome endpoints. These findings provide strong support for the advancement of RBT-1 into a pivotal Phase 3 study.

RBT-1 has been granted Breakthrough Therapy designation status by the U.S. Food and Drug Administration (FDA) specifically for reducing the risk of complications in patients undergoing cardiothoracic surgery. 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024